Myasnikov A L, Berns S A, Talyzin P A, Ershov F I
Moscow SBIH City Clinical Hospital named after M.E. Zhadkevich of the Moscow City Health Department.
FSBI National Research Centre of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya of the Ministry of Health of Russia.
Vopr Virusol. 2021 Mar 7;66(1):47-54. doi: 10.36233/0507-4088-24.
Interferons are produced in response to the presence of pathogens in cells and are responsible for the proper formation of immune reaction. Preliminary data obtained in studies of properties of recombinant interferon gamma (IFN-γ) that involved patients with community-acquired pneumonia (including bacterial), acute respiratory viral infection (ARVI), influenza and new coronavirus infection have shown promising results.The purpose of the study was to assess the effect of subcutaneous administration of IFN-γ in patients with viral pneumonia on the changes of vital signs and the duration of hospital stay.
An open-label, randomized, low-interventional study included patients with moderate new coronavirus infection COVID-19 over 18 years of age of both sexes. IFN-γ 500,000 IU was administered s/c, daily, once a day, during 5 days.
IFN-y in addition to complex therapy of the disease resulted in more favorable changes in the stabilization of vital signs, as well as in reduced length of fever and hospital stay by 2 days what allows suggesting a positive effect of this substance on the recovery processes in patients with moderate COVID-19. Special emphasis should be made to the fact that patients who received recombinant IFN- γ experienced no progression of respiratory failure and required no transfer to intensive care unit.
This study confirms earlier obtained data on the positive effect of IFN-y on the rate of clinical stabilization and recovery of patients with community-acquired pneumonia and viral infections. Presented results are limited to a small number of patients; further study of drug properties in post-marketing studies is required.
Progress in the treatment of patients with moderate COVID-19 by adding recombinant IFN-γ to the complex therapy may reasonably expand the range of existing treatment options for this infection.
干扰素是细胞在病原体存在时产生的，负责免疫反应的正常形成。在对重组干扰素γ（IFN-γ）特性的研究中获得的初步数据表明，该研究涉及社区获得性肺炎（包括细菌性肺炎）、急性呼吸道病毒感染（ARVI）、流感和新型冠状病毒感染的患者，结果显示出了有前景的效果。本研究的目的是评估皮下注射IFN-γ对病毒性肺炎患者生命体征变化和住院时间的影响。
一项开放标签、随机、低干预性研究纳入了年龄超过18岁的男女新型冠状病毒感染COVID-19中度患者。每天皮下注射500,000国际单位的IFN-γ，持续5天，每日一次。
IFN-γ除了对疾病进行综合治疗外，还使生命体征稳定方面出现了更有利的变化，发热时间和住院时间缩短了2天，这表明该物质对中度COVID-19患者的康复过程有积极作用。应特别强调的是，接受重组IFN-γ治疗的患者没有出现呼吸衰竭进展，也不需要转入重症监护病房。
本研究证实了先前获得的关于IFN-γ对社区获得性肺炎和病毒感染患者临床稳定率和康复有积极作用的数据。目前的结果仅限于少数患者；需要在上市后研究中进一步研究药物特性。
通过在综合治疗中添加重组IFN-γ来治疗中度COVID-19患者的进展可能合理地扩大这种感染现有治疗选择的范围。
